An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Abstract

The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 ClinicalTrials.gov number, NCT04283461).

Keywords

VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakMedicineOutbreakInfectious disease (medical specialty)Internal medicine

Affiliated Institutions

Related Publications

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson , Nadine Rouphael , Alicia T. Widge +34 more

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutra...

2020 New England Journal of Medicine 1581 citations

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Lindsey R. Baden , Hana M El Sahly , Brandon Essink +34 more

The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were ...

2020 New England Journal of Medicine 10252 citations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack , Stephen J. Thomas , Nicholas Kitchin +26 more

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral...

2020 New England Journal of Medicine 14917 citations

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S. Corbett , Barbara J. Flynn , Kathryn E. Foulds +71 more

Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in th...

2020 New England Journal of Medicine 1134 citations

Publication Info

Year: 2020
Type: article
Volume: 383
Issue: 20
Pages: 1920-1931
Citations: 3382
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3382

OpenAlex

Cite This

APA Style

                            
                                
                                    Lisa A. Jackson, 
                                
                                    Evan J. Anderson, 
                                
                                    Nadine Rouphael
                                
                                et al.
                            
                            (2020). 
                            An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. 
                            New England Journal of Medicine
                            , 383
                            (20)
                            , 1920-1931.
                            https://doi.org/10.1056/nejmoa2022483
                        

Identifiers

DOI: 10.1056/nejmoa2022483